Search

Your search keyword '"Calmy A."' showing total 348 results

Search Constraints

Start Over You searched for: Author "Calmy A." Remove constraint Author: "Calmy A." Topic business.industry Remove constraint Topic: business.industry
348 results on '"Calmy A."'

Search Results

1. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

3. Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in Eswatini

4. Brief Report: Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell Therapies

5. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

6. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV‐positive people without viral hepatitis in the Swiss HIV Cohort Study

7. Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study

8. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality-a multicentre prospective cohort study

9. The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland

10. Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity

11. Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor–Based Antiretroviral Treatment

12. Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV

13. Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study

14. Evolocumab in HIV-Infected Patients With Dyslipidemia

15. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)

16. Children living with HIV in Europe: do migrants have worse treatment outcomes?

17. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

18. Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis

19. High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus

20. Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV

21. Cardiovascular risk assessment in people living with HIV compared to the general population

22. The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study

23. Prevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study

24. Weight gain stopping/switch rules for antiretroviral clinical trials

25. Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs

26. Kaposi sarcoma in ART-treated people living with HIV

27. Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy

28. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

29. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

30. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

31. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study

32. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk; a randomised, controlled trial

33. Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial

34. Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk group

35. The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study

36. Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS)

37. Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland

38. Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection

39. Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus

40. Efficacy of Lopinavir-Ritonavir Prophylaxis for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial

41. Caring for people living with HIV during the global coronavirus disease 2019 pandemic

42. Prophylaxis for COVID-19: a systematic review

43. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis

44. Healthcare delivery for HIV-positive people with tuberculosis in Europe

45. Dexamethasone and remdesivir: finding method in the COVID-19 madness

46. Prevalence of potential drug-drug interactions in patients of the Swiss HIV cohort study in the era of HIV integrase inhibitors

47. Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection

48. Author Correction: HIV and antiretroviral therapy-related fat alterations

49. Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients

50. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID‐19: initial assessment

Catalog

Books, media, physical & digital resources